🧬 There's a cruel arithmetic buried inside spinal cord injury. The people most likely to benefit from an experimental cell therapy are the ones who were hurt a few weeks ago. The people who were paralyzed years ago — the overwhelming majority — have long been told, gently but firmly, that regeneration just isn't on the table for them. A team in Tokyo now wants to erase that line.

From the "treatable window" to everyone else

Back in 2019, Keio University launched the world's first clinical study to transplant iPS-derived neural progenitor cells into people with spinal cord injuries. (iPS cells are the reprogrammable "blank" cells Kyoto's Shinya Yamanaka won a Nobel Prize for in 2012, grown from ordinary skin or blood and coaxed into almost any tissue.) The neural progenitor cells are their half-finished descendants: not yet neurons, but already committed to becoming nerve tissue.

There was a catch. The study only accepted patients in the subacute phase, roughly 14 to 28 days after the injury. It performed its first transplant in December 2021, and in March 2025 the group announced it had finished observing all four participants. Safety held up, and one patient who had been unable to move regained enough function to stand. The researchers said the next step would be a formal clinical trial.

That covers the fresh injuries. The much harder question is what to do about everyone else, and that's the news. At the annual meeting of the Japanese Society for Regenerative Medicine on March 19, 2026, Keio physician Keiko Sugai laid out plans for a physician-led trial aimed squarely at chronic spinal cord injury, using allogeneic (donor-derived) iPS neural progenitor cells. The trial is still in preparation, not yet enrolling patients. But the ambition is the milestone: dragging regenerative medicine past the narrow window where it's "supposed" to work.

Why doctors quietly wrote off chronic paralysis

To understand why chronic is the frontier, it helps to know what happens to a spinal cord after it's crushed, usually in a traffic accident or a fall.

In the first weeks, the injury site is chaotic but still biologically "open." Transplanted cells can find room to settle, wire in, and coax surviving circuits back to life. That's the subacute window.

Give it months or years, and the neighborhood turns hostile. The body seals off the damage with dense scar tissue, and fluid-filled cavities can form where working cord used to be. The local chemistry actively discourages nerves from growing. In practice, this is why standard care for long-term spinal injury has been rehabilitation to preserve whatever function remains, not repair, and why patients years past their injury were, in effect, told there was nothing left to try. Keio's own researchers describe reaching those chronic patients as the central problem of the entire field.

Turning scar tissue back into something a nerve can grow through

You can't just take the subacute recipe and use it later. As Keio's Hideyuki Okano has put it, the chronic phase calls for iPS-derived neural progenitor cells with different properties, tuned for a much rougher environment.

Two ideas from the lab explain the approach. The first is a pre-treatment step. In animal work reported through Japan's medical research agency AMED, the team leaned on a signal called Notch, which keeps progenitor cells in a self-renewing, undifferentiated state. Blocking it with a gamma-secretase inhibitor (a compound first developed as an Alzheimer's drug) nudged the cells to stop multiplying and start becoming neurons. Cells prepped this way produced more new neurons and axons (the long fibers that carry nerve signals) and better remyelination (rebuilding the insulating sheath that lets signals travel). In animal models, that added up to reconstructed spinal circuits and recovered movement.

The second idea is to fix the soil, not just the seed. In a 2023 study in the journal Inflammation and Regeneration, the group treated chronically injured rats (roughly three months post-injury) with the cells plus HGF, a protective molecule (hepatocyte growth factor). The combination worked better than either the cells or the molecule alone: in treated animals, the scarring and cavities that mark a chronic injury were noticeably reduced. The strategy, in other words, is to soften the hostile microenvironment first, then give the new cells a fighting chance to integrate.

5,000 versus 100,000

Here's why the stakes jump. Roughly 5,000 people a year in Japan sustain a new spinal cord injury, the pool that could, in principle, be caught inside the subacute window. The chronic population is a different order of magnitude: an estimated 100,000 to 200,000 people already living with long-term spinal injury.

A therapy that only worked in the first few weeks would always reach a sliver of those affected. Cracking the chronic phase is what would turn a striking proof of concept into help for the majority who were told to stop hoping.

The country that keeps getting there first

None of this is happening in a vacuum. Japan has spent two decades building the scaffolding around Yamanaka's 2006 discovery: Kyoto University's ready-made "iPS cell stock" (the same donor-derived starting material used to make the transplant cells), and a tight loop of universities, government funding, and industry.

And 2026 is the year that groundwork started paying off in products, not just papers. In March, Japan granted the world's first approvals for iPS-derived regenerative medicines: Amchepry, Sumitomo Pharma's cell therapy for Parkinson's disease, and ReHeart, Cuorips' iPS-derived heart-muscle sheet for severe heart failure. Both came through Japan's distinctive "conditional and time-limited" approval route, valid for seven years while more evidence is gathered. The spinal cord trial is being prepared against that backdrop, a moment when iPS medicine is visibly crossing from the lab into the clinic.

What this is not — at least not yet

A few guardrails, because this is exactly the kind of story that gets oversold.

The chronic trial hasn't started; it's being prepared. Even the subacute work is at the "safety looks okay, efficacy still to be proven" stage. Nobody involved is claiming a cure. Keio's Masaya Nakamura, who has fielded letters from families of chronic patients, has been blunt about the "magic cell" myth: the belief that iPS cells will suddenly make legs work again. Cell transplantation, he stresses, is one piece of the puzzle; rehabilitation to keep muscles and stamina ready for that future is another, and it's non-negotiable.

There's also the money and the debate around it. Japan's conditional-approval pathway, which let Amchepry and ReHeart reach patients on limited data, has drawn real criticism from those who worry the bar for proof is too low, and the prices are startling. Amchepry's Parkinson's therapy was set at ¥55.3 million (around $340,000) when it gained insurance coverage. What a chronic spinal cord therapy would eventually cost, and who would pay, is a question for another day, but it's already on the table.

In Japan, the story of spinal cord regeneration has moved from "impossible" to "in preparation" in a single decade, and yet the researchers driving it keep stressing how far there still is to go. How advanced is regenerative medicine for spinal cord injury where you live? And if a trial like this opened tomorrow, would patients in your country actually have a way to take part?

References